Cargando…
Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength
We have examined the effects of intravenous (IV) delivery of rAAVrh74.MHCK7.GALGT2 in the golden retriever muscular dystrophy (GRMD) model of Duchenne Muscular Dystrophy (DMD). After baseline testing, GRMD dogs were treated at 3 months of age and reassessed at 6 months. This 3–6 month age range is a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997012/ https://www.ncbi.nlm.nih.gov/pubmed/33770101 http://dx.doi.org/10.1371/journal.pone.0248721 |
_version_ | 1783670230893985792 |
---|---|
author | Martin, Paul T. Zygmunt, Deborah A. Ashbrook, Anna Hamilton, Sonia Packer, Davin Birch, Sharla M. Bettis, Amanda K. Balog-Alvarez, Cynthia J. Guo, Lee-Jae Nghiem, Peter P. Kornegay, Joe N. |
author_facet | Martin, Paul T. Zygmunt, Deborah A. Ashbrook, Anna Hamilton, Sonia Packer, Davin Birch, Sharla M. Bettis, Amanda K. Balog-Alvarez, Cynthia J. Guo, Lee-Jae Nghiem, Peter P. Kornegay, Joe N. |
author_sort | Martin, Paul T. |
collection | PubMed |
description | We have examined the effects of intravenous (IV) delivery of rAAVrh74.MHCK7.GALGT2 in the golden retriever muscular dystrophy (GRMD) model of Duchenne Muscular Dystrophy (DMD). After baseline testing, GRMD dogs were treated at 3 months of age and reassessed at 6 months. This 3–6 month age range is a period of rapid disease progression, thus offering a relatively short window to establish treatment efficacy. Measures analyzed included muscle AAV transduction, GALGT2 transgene expression, GALGT2-induced glycosylation, muscle pathology, and muscle function. A total of five dogs were treated, 4 at 2x10(14)vg/kg and one at 6x10(14)vgkg. The 2x10(14)vg/kg dose led to transduction of regions of the heart with 1–3 vector genomes (vg) per nucleus, while most skeletal muscles were transduced with 0.25–0.5vg/nucleus. GALGT2-induced glycosylation paralleled levels of myofiber vg transduction, with about 90% of cardiomyocytes having increased glycosylation versus 20–35% of all myofibers across the skeletal muscles tested. Conclusions from phenotypic testing were limited by the small number of dogs. Treated dogs had less pronounced fibrosis and overall lesion severity when compared to control groups, but surprisingly no significant changes in limb muscle function measures. GALGT2-treated skeletal muscle and heart had elevated levels of utrophin protein expression and GALGT2-induced expression of glycosylated α dystroglycan, providing further evidence of a treatment effect. Serum chemistry, hematology, and cardiac function measures were largely unchanged by treatment. Cumulatively, these data show that short-term intravenous treatment of GRMD dogs with rAAVrh74.MHCK7.GALGT2 at high doses can induce muscle glycosylation and utrophin expression and may be safe over a short 3-month interval, but that such treatments had only modest effects on muscle pathology and did not significantly improve muscle strength. |
format | Online Article Text |
id | pubmed-7997012 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-79970122021-04-06 Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength Martin, Paul T. Zygmunt, Deborah A. Ashbrook, Anna Hamilton, Sonia Packer, Davin Birch, Sharla M. Bettis, Amanda K. Balog-Alvarez, Cynthia J. Guo, Lee-Jae Nghiem, Peter P. Kornegay, Joe N. PLoS One Research Article We have examined the effects of intravenous (IV) delivery of rAAVrh74.MHCK7.GALGT2 in the golden retriever muscular dystrophy (GRMD) model of Duchenne Muscular Dystrophy (DMD). After baseline testing, GRMD dogs were treated at 3 months of age and reassessed at 6 months. This 3–6 month age range is a period of rapid disease progression, thus offering a relatively short window to establish treatment efficacy. Measures analyzed included muscle AAV transduction, GALGT2 transgene expression, GALGT2-induced glycosylation, muscle pathology, and muscle function. A total of five dogs were treated, 4 at 2x10(14)vg/kg and one at 6x10(14)vgkg. The 2x10(14)vg/kg dose led to transduction of regions of the heart with 1–3 vector genomes (vg) per nucleus, while most skeletal muscles were transduced with 0.25–0.5vg/nucleus. GALGT2-induced glycosylation paralleled levels of myofiber vg transduction, with about 90% of cardiomyocytes having increased glycosylation versus 20–35% of all myofibers across the skeletal muscles tested. Conclusions from phenotypic testing were limited by the small number of dogs. Treated dogs had less pronounced fibrosis and overall lesion severity when compared to control groups, but surprisingly no significant changes in limb muscle function measures. GALGT2-treated skeletal muscle and heart had elevated levels of utrophin protein expression and GALGT2-induced expression of glycosylated α dystroglycan, providing further evidence of a treatment effect. Serum chemistry, hematology, and cardiac function measures were largely unchanged by treatment. Cumulatively, these data show that short-term intravenous treatment of GRMD dogs with rAAVrh74.MHCK7.GALGT2 at high doses can induce muscle glycosylation and utrophin expression and may be safe over a short 3-month interval, but that such treatments had only modest effects on muscle pathology and did not significantly improve muscle strength. Public Library of Science 2021-03-26 /pmc/articles/PMC7997012/ /pubmed/33770101 http://dx.doi.org/10.1371/journal.pone.0248721 Text en © 2021 Martin et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Martin, Paul T. Zygmunt, Deborah A. Ashbrook, Anna Hamilton, Sonia Packer, Davin Birch, Sharla M. Bettis, Amanda K. Balog-Alvarez, Cynthia J. Guo, Lee-Jae Nghiem, Peter P. Kornegay, Joe N. Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength |
title | Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength |
title_full | Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength |
title_fullStr | Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength |
title_full_unstemmed | Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength |
title_short | Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength |
title_sort | short-term treatment of golden retriever muscular dystrophy (grmd) dogs with raavrh74.mhck7.galgt2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997012/ https://www.ncbi.nlm.nih.gov/pubmed/33770101 http://dx.doi.org/10.1371/journal.pone.0248721 |
work_keys_str_mv | AT martinpault shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength AT zygmuntdeboraha shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength AT ashbrookanna shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength AT hamiltonsonia shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength AT packerdavin shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength AT birchsharlam shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength AT bettisamandak shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength AT balogalvarezcynthiaj shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength AT guoleejae shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength AT nghiempeterp shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength AT kornegayjoen shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength |